Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$83.14 - $145.99 $68.2 Million - $120 Million
-820,470 Reduced 39.8%
1,240,932 $181 Million
Q1 2022

May 16, 2022

SELL
$110.08 - $142.92 $1.54 Million - $2 Million
-14,000 Reduced 0.67%
2,061,402 $244 Million
Q4 2021

Feb 14, 2022

SELL
$99.73 - $148.48 $4.85 Million - $7.22 Million
-48,653 Reduced 2.29%
2,075,402 $286 Million
Q3 2021

Nov 15, 2021

BUY
$98.85 - $138.91 $4.1 Million - $5.76 Million
41,500 Added 1.99%
2,124,055 $295 Million
Q2 2021

Aug 16, 2021

SELL
$65.78 - $105.02 $2.68 Million - $4.28 Million
-40,716 Reduced 1.92%
2,082,555 $202 Million
Q1 2021

May 17, 2021

SELL
$64.07 - $91.75 $1.6 Million - $2.29 Million
-25,000 Reduced 1.16%
2,123,271 $145 Million
Q4 2020

Feb 16, 2021

BUY
$65.07 - $98.24 $4.78 Million - $7.22 Million
73,471 Added 3.54%
2,148,271 $184 Million
Q3 2020

Nov 16, 2020

BUY
$59.04 - $77.95 $3.73 Million - $4.92 Million
63,100 Added 3.14%
2,074,800 $135 Million
Q2 2020

Aug 14, 2020

BUY
$29.01 - $74.23 $4.09 Million - $10.5 Million
140,957 Added 7.53%
2,011,700 $147 Million
Q1 2020

May 15, 2020

SELL
$27.51 - $57.29 $1.45 Million - $3.01 Million
-52,547 Reduced 2.73%
1,870,743 $63.7 Million
Q4 2019

Feb 14, 2020

BUY
$40.86 - $57.65 $5.86 Million - $8.27 Million
143,415 Added 8.06%
1,923,290 $105 Million
Q3 2019

Nov 14, 2019

BUY
$37.38 - $49.47 $4 Million - $5.29 Million
106,925 Added 6.39%
1,779,875 $74.3 Million
Q2 2019

Aug 14, 2019

BUY
$39.79 - $67.01 $25.9 Million - $43.7 Million
651,558 Added 63.79%
1,672,950 $73.3 Million
Q1 2019

May 15, 2019

BUY
$34.52 - $53.29 $29.2 Million - $45.1 Million
846,857 Added 485.21%
1,021,392 $52.6 Million
Q4 2018

Feb 14, 2019

BUY
$29.75 - $42.9 $5.19 Million - $7.49 Million
174,535 New
174,535 $6.45 Million

Others Institutions Holding BHVN

About Biohaven Pharmaceutical Holding Co Ltd.


  • Ticker BHVN
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,645,000
  • Market Cap $2.8B
  • Description
  • Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...
More about BHVN
Track This Portfolio

Track Oracle Investment Management Inc Portfolio

Follow Oracle Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Oracle Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Oracle Investment Management Inc with notifications on news.